Effects of teriparatide on cementless bipolar hemiarthroplasty in patients with osteoporotic femoral neck fractures

Tsan-Wen Huang 1,4, Kuo-Chin Huang 1,4, Shih-Jie Lin 1, Po-Yao Chuang 1, Hsin-Nung Shih 3,4, Mel S. Lee 2,4*, Robert Wen-Wei Hsu 1,4* and Wun-Jer Shen 5

Abstract

Background: For osteoporotic femoral neck fractures, suitable bone-implant stability is critical for pain relief, early return to daily activities and reduction of complications. Teriparatide (parathyroid hormone [PTH1-34]) can improve bone-implant stability in some basic studies. However, its use in osteoporotic femoral neck fractures treated by cementless hemiarthroplasties for the beneficial effects on bone-implant stability is sparse in the literature. The aim of this study was to determine if post-operative teriparatide administration can reduce femoral stem migration and improve early functional recovery and health-related quality of life (HRQoL).

Methods: Between 2010 and 2014, patients with osteoporotic femoral neck fracture who underwent cementless bipolar hemiarthroplasty were included into this retrospective cohort study. Group A included patients treated with cementless bipolar hemiarthroplasty only; Group B patients had additional teriparatide. Demographic data, complications, radiographic and functional outcomes as well as health-related quality of life (HRQoL) were compared.

Results: There were 52 hips in group A (no teriparatide) and 40 hips in group B (patient who received teriparatide). The subsidence of the femoral stem tended to be significantly decreased in the teriparatide group at 6 and 12 weeks post-operatively ($p = 0.003$ and $p = 0.008$, respectively). The Harris Hip Score (HHS) increased significantly from pre-operation to 6 weeks post-operatively and thereafter up to one year in both groups. However, there were no significant differences in terms of subsequent fracture, mortality, HHS, and HRQoL between two groups during the entire study period.

Conclusions: Teriparatide significantly reduces the subsidence of the cementless femoral stem in elderly patients in the early post-operative period, but this benefit does not reflect better functional outcomes and HRQoL. Further prospective randomized large-scale cohort study is warranted for evidence-based recommendations.

Keywords: Osteoporosis, Teriparatide, Femoral neck fracture, Hip arthroplasty, Implant migration

Background

Femoral neck fracture is one of the most common osteoporotic hip fractures [1]. Displaced femoral neck fracture has been treated traditionally with cemented or cementless hemiarthroplasty, with the goal of accomplishing pain relief and early recovery of daily activities, which are critical for avoiding complications [2]. Cementless hemiarthroplasty has gained substantial popularity in past decades as it helps solve problems pertaining to cemented implants [3]. Achieving immediate stability of the implant is vital for the success of cementless hemiarthroplasty. However, decreased bone regenerative capacity and poor bone stock may affect biologic fixation in elderly patients [4].

Bisphosphonate (BP) has been demonstrated to possess anti-fracture efficacy, preventing peri-prosthetic bone loss [5] and lowering the risk of revision surgery after hip

* Correspondence: bone@doctor.com; wwh@adm.cgmh.org.tw

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
arthroplasty [6]. Recent results with the use of zoledronic acid, a long-acting BP, in reducing migration of the femoral stem have been encouraging [7, 8]; however, the incidence of subsidence of the femoral stem remains high among the elderly [7]. Teriparatide (parathyroid hormone [PTH1-34]), approved by the U.S. Food and Drug Administration (FDA) in 2002, promotes the active building of bone mass via stimulation of the proliferation and differentiation of osteoprogenitor cells [9]. Recent animal studies reveal an acceleration of fracture healing and improvement of bone-implant stability in teriparatide-treated animals [10]. In some human trials, teriparatide appears to enhance fracture healing [11], accelerate lumbar postero-lateral fusion [12], lessen the risk of pedicle screw loosening [13], and increase the purchase of the pedicle screws to the bone [14].

In theory, the positive impact of teriparatide on bone-implant stability is important for an early return to daily activities and reducing morbidity and mortality. This retrospective study was aimed to determine if post-operative teriparatide administration can reduce femoral stem migration and improve early functional recovery and health-related quality of life (HRQoL). Additional correlation analyses were also conducted to determine the role of supplementary teriparatide in reducing complications and mortality in osteoporotic femoral neck fracture.

Methods
Clinical and demographic data
This retrospective study was approved by the Ethics Committee and Institutional Review Board of the Chang Gung Memorial Hospital (98-1038B), and all patients provided signed informed consent.

All patients who underwent surgery for osteoporotic femoral neck fracture at our institution since 2010 were routinely entered into the osteoporosis management program. Pharmacologic management, including calcium and vitamin D supplements, anti-resorption drugs and osteo-anabolic drugs, was offered. The merits, disadvantages, and risks of osteoporosis treatment were based on the International Osteoporosis Foundation (IOF) Guidelines for Osteoporosis Treatment [15] and were explained to the patients. The choice of osteoporosis treatments was decided by the patients themselves. Drug use information was included in the computerized database.

We manually reviewed patient records in our database to identify all patients who met the indication of teriparatide treatment (based on IOF Guidelines for Osteoporosis Treatment [15]). To minimize surgeon-related confounding factors, all cementless bipolar hemiarthroplasties were performed by the same surgeon. All patients underwent standardized hemiarthroplasty via a direct lateral approach. On the basis of the standard of care following cementless hemiarthroplasty, the patients were encouraged to ambulate with partial weight-bearing as soon as possible after surgery. To minimize implant-related confounding factors, the patients were treated with the same prosthesis (PROFEMUR® Z hip stem, Wright Medical Technology, Inc. Canadian). The stem had a double-tapered design with grit-blasted surface processing and a rectangular shape that fit at the metaphyseal-diaphyseal junction and proximal diaphysis (Fig. 1a). To minimize drug-related variables, patients who received anti-osteoprotic drugs before surgery were excluded.

Patients with (1) a minimum follow-up of <12 months; (2) multiple fractures, pathologic fractures, previous ipsilateral hip or femur surgery, or fracture of the contralateral hip; (3) musculoskeletal conditions that altered bone conditions, like arthrogryposis multiplex congenita, poliomyelitis, cerebral palsy, developmental abnormality, and Down syndrome; (4) contraindication to the use of teriparatide; (5) complications related to teriparatide use, such as generalized weakness and hypercalcemia; (6) minimum teriparatide treatment course of <12 months; (7) inability to ambulate pre-operatively; and (8) incomplete medical records, radiographic analyses, and clinical functional assessments, were excluded.

The patients were then divided into two subgroups: those who received only calcium and vitamin D supplements (600 mg of calcium and 800 international units (IU) of vitamin D3 per day) (Group A) and those who post-operatively received teriparatide and calcium and vitamin D supplements (Group B). To determine adequate sample size, a priori power analysis using the hypothesis test with a power of 80 % and significance of 0.05 was performed. Based on Friedl et al. [7], a pre-study sample size calculation of 24 patients was required in each group to detect a difference in implant migration of 0.5 mm/yr with a power of 80 % at a 5 % significance level. According to Achten et al. [16], 28 hips were required per group to detect a difference of 10 points in the Harris Hip Score (HHS) (estimated Standard deviation of 13). The cut-off value was selected because a difference of 10 points was suggested as the minimal clinically important difference.

Assessments
Radiographic assessment
All patients enrolled in this study were assessed by radiographic examination, including antero-posterior (AP) views of the pelvis and lateral views of the affected hip pre-operatively, immediately after surgery and post-operatively at 6 and 12 weeks, 6 and 12 months, and then yearly. Radiographic evaluation of the hip prosthesis was performed with each standard pelvis AP and lateral projection according to the system described by Engh, Massin, & Suthers [17] and Johnston et al. [18]. Using post-operative radiographs, we recorded the position of the femoral stem (valgus, neutral or varus), implant
migration (Fig. 1), femoral stem-canal ratio (Fig. 2) [19], radiolucent lines around the prosthesis, and pedestal formation of the unstable stem. A stem migration of 0.6 mm was considered a clinically important difference and was defined as femoral stem subsidence, based on Thomas Baad-Hansen et al. [20].

Bone mineral density (BMD) of the opposite hip was measured using the Hologic DXA QDR 4500 (Hologic Inc., Waltham, MA) after surgery. The radiographic assessments and BMD of the opposite hip were reviewed and analyzed by an independent surgeon who was blinded to the groupings and patient demographic data. Intra-observer reliability was assessed according to the method described by Konigsberg et al. [21], and rated as good to very good.

**Functional assessment**

Pre-operative surgical risk was categorized according to the classification of the American Society of Anesthesiologists (ASA). Functional assessments including the HHS and Short-Form-12 (SF-12) were performed at pre-injury and at post-operative 3, 6, 9, and 12 months. The SF-12 is a HRQoL scale composed of 12 questions. Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were estimated by the assignment of different weights to the questions. A higher score was related to a better outcome. All functional outcomes were assessed by an independent observer who was also blinded to the groupings and patient demographic data.

Complications and use of analgesics were recorded. Any medical or surgical event that compromised the clinical recovery of patients, such as wound infection, pneumonia, urinary tract infection, venous thromboembolism (VTE), neurovascular injury, fracture, dislocation, implant malposition, implant size mismatch, or early loosening, was defined as an adverse event. A relatively poorer and slower functional recovery beyond 3 months and an HHS score <80 were also categorized as adverse events.

**Statistical analyses**

All data were collected and independently entered into a Microsoft Excel spreadsheet by an independent observer.
After the spreadsheets were re-checked for missing and illogical data, the data were copied into SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL) and analyzed. Student's t test was used to compare the variables of age, body mass index, hospital stay, BMD of contralateral hip, femoral stem-canal ratio, follow-up time, subsidence of stem, and functional results. Between-group comparisons of continuous variables at each time point were analyzed using the Mann-Whitney U test, while within-group comparisons between time points and baseline values were performed using the Wilcoxon signed-rank test. Categorical data were analyzed using the chi-square test and Fisher's exact test, as appropriate. All data were analyzed by an independent statistician who was blinded to the grouping, patient demographic data, and function outcomes. Significance was set at $p < 0.05$.

**Fig. 2** Assessment of the femoral stem-canal ratio. A line was drawn along the lateral margin of the lateral cortex and extended, and then the width between this line and the medial cortex was measured (C-D). Femoral stem-canal ratio was defined as the ratio of the width of the femoral component to the width of the medullary canal (E-F/C-D). Satisfactory was recorded when the ratio was more than 80%. Radiographic evaluation originally appeared in J Bone Joint Surg Br 1993;75:6-13. E-F: the width of the femoral component.
Results
Between 2010 and 2014, 112 patients (112 hips) met our inclusion criteria. However, 14 patients who used anti-osteoporotic drugs prior to surgery and 6 with incomplete data were excluded, leaving 92 patients (92 hips), including 52 in Group A (no teriparatide) and 40 in Group B (treated with teriparatide), for further analysis. The mean follow-up time was 38.4 months (range, 12–59 months). There were no differences in age, body mass index, ASA classification, hospital stay, BMD of the contralateral hip, femoral stem-canal ratio, and follow-up time between the two groups (Table 1).

There was no difference between complications of the two groups, except for subsidence rates ($p = 0.028$). A summary of complications during the 12-month follow-up revealed no deep wound infection, VTE, intra-operative peri-prosthetic fracture, early loosening of the femoral stem, or dislocation had occurred in either group (Table 2). Both groups showed similar findings with regard to superficial wound infection, pneumonia, urinary tract infection, and post-operative peri-prosthetic fracture. Six patients in Group A and four patients in Group B died during the follow-up period due to reasons unrelated to the operation ($p = 0.545$). The overall complication rate between the two groups was significantly different ($p = 0.020$) (Table 2).

Twenty-three patients (13 in Group A and 10 in Group B) were excluded from the final analysis: ten patients died (6 in Group A and 4 in Group B), one had post-operative peri-prosthetic fracture (Group B), and 12 had sustained subsequent fracture, including vertebral fracture in 6 patients (4 in Group A and 2 in Group B).

Table 1 Demographic Data of the Teriparatide and Control Groups

| Parameters                  | Group A   | Group B   | $p$ value |
|-----------------------------|-----------|-----------|-----------|
| Age at time of operation (yrs) | 71.0 ± 8.3 | 72.1 ± 7.6 | 0.682 |
| Body mass index (kg/m²)       | 26.9 ± 2.5 | 25.9 ± 3.1 | 0.693 |
| ASA classification            | 0.829     |           |           |
| ASA I                        | -         | -         |           |
| ASA II                       | 33 (63.5 %) | 24 (60.0 %) | 0.693 |
| ASA III                      | 19 (36.5 %) | 16 (40.0 %) |           |
| Hospital stay (day)           | 7.3 ± 1.6 | 6.9 ± 1.6 | 0.464 |
| BMD of contralateral hip (T-score) | -4.3 ± 1.2 | -4.2 ± 1.0 | 0.908 |
| Femoral stem-canal ratio (%)  | 88.3 ± 5.2 | 87.6 ± 5.3 | 0.620 |
| Follow-up (months)            | 27.1 ± 7.3 | 26.2 ± 7.4 | 0.650 |

Group A: patients without supplementary pharmacologic treatment
Group B: patients treated with teriparatide

Values are shown as mean (standard deviation) or as the n (%)
$p$-values for between-group comparisons were determined by the chi-squared test and Fisher’s exact test for categorical variables and Student’s t test for continuous variables

*Statistically significant ($p < 0.05$)

Table 2 Post-operative Complications in the Teriparatide and Control Groups

| Variables                       | Group A   | Group B   | $p$ value |
|--------------------------------|-----------|-----------|-----------|
| Overall complications           | 30 (57.7 %) | 14 (35.0 %) | 0.020* |
| Post-operative peri-prosthetic fracture | 0         | 1 (2.5 %)  | 0.435 |
| Subsidence of the femoral stem  | 18 (34.6 %) | 6 (15.0 %)  | 0.028* |
| Early loosening                 | 0         | 0         | -         |
| Dislocation                     | 0         | 0         | -         |

Group A: patients without supplementary pharmacologic treatment
Group B: patients treated with teriparatide

The values are given as the n (%)

$p$-values for between-group comparisons were determined by the chi-squared test and Fisher’s exact test

*Statistically significant ($p < 0.05$)

Discussion
The most important finding in this investigation is that teriparatide use lessens the subsidence of cementless femoral stems compared to non-use of teriparatide in...
the early post-operative period (6 and 12 weeks, post-operatively). However, this benefit does not translate to better functional outcomes and HRQoL. There was no statistically significant difference between the two groups in subsequent fracture and mortality.

Osteoporotic femoral neck fractures often contribute to pain and immobility and lead to a loss of ability to perform daily activities and a reduction in quality of life, which are associated with high morbidity and mortality [22, 23]. The annual number of these fractures worldwide, as estimated by the IOF, will be as high as 4.6 million by 2025 and 6.26 million by 2050 [23]. This injury is relatively common and is a serious clinical issue affecting the elderly; it is a burden on individuals and on the health-care system, as well as society in general [1, 22, 23]. The primary treatment goals are pain relief, improvement in mobilization and the prevention of complications, which are of critical importance [1, 2]. However, this is also a challenge for orthopedic surgeons because of decreased bone regenerative capacity and poor bone stock [4].

In treating osteoporotic femoral neck fractures, the orthopedic surgeon is often the first physician to address the injury and is in a unique position to make every effort to treat, prevent subsequent fractures, and minimize the need for subsequent revision surgery [1, 2, 5–8]. Since bipolar hemiarthroplasty is commonly performed in elderly patients with femoral neck fracture, post-operative administration of anti-osteoporotic drugs is reasonable and may play a valuable role in the treatment [1, 2]. Among these anti-osteoporotic drugs, BP is widely used and has been demonstrated to prevent peri-prosthetic bone loss [5, 8, 24], lower the risk of revision surgery after hip arthroplasty [6], and reduce femoral stem migration [7, 8]. However, subsidence of the femoral stem is still higher in elderly patients [7]. Moreover, concerns exist regarding BP-induced osteonecrosis of the jaw, atypical femoral fracture, and atypical peri-prosthetic fracture after long-term BP treatment [25, 26].

Osteoblast activity may play an important role in osteo-integration between bone and prosthesis [27]. The anabolic agent teriparatide was approved by the U.S. FDA in 2002, and was indicated for the treatment of osteoporosis in men and in post-menopausal women [1]. Unlike anti-resorption drugs, teriparatide was found to directly stimulate osteoblasts to increase trabecular

| Parameters                  | Group A          | Group B          | p value |
|-----------------------------|------------------|------------------|---------|
| N = 52                      | N = 40           |                  |         |
| Subsequent fracture         |                  |                  |         |
| Vertebral fracture          | 4 (7.7 %)        | 2 (5.0 %)        | 0.470   |
| Hip fracture                | 1 (1.9 %)        | 1 (2.5 %)        | 0.683   |
| Wrist fracture              | 2 (3.8 %)        | 2 (5.0 %)        | 0.587   |
| Overall subsequent fractures| 7 (13.5 %)       | 5 (12.5 %)       | 0.574   |

Group A: patients without supplementary pharmacologic treatment
Group B: patients treated with teriparatide

The values are given as the n (%)
*p*-values for between-group comparisons were determined by the chi-squared test and Fisher’s exact test
*Statistically significant (*p* < 0.05)

---

![Fig. 3](image-url)  
**Fig. 3** The migration pattern of the femoral components. The values are the mean for the teriparatide and control groups on follow-up intervals immediately after surgery and at 6 and 12 weeks and 6 and 12 months. The subsidence of the stem was significantly decreased in the teriparatide group compared to the control group at each time point. The distal migration of the stem reached a plateau phase at 6 months and 12 months post-operatively in both groups. *p < 0.05, Mann-Whitney U test**
connectivity, cortical thickness, and bone mineral content in the peri-implant area, thereby accelerating fracture healing and lumbar postero-lateral fusion and improving bone-implant stability in treated animals [9, 10] and in human trials [11–14]. In animal studies, finite element analysis, and human trials, teriparatide showed superiority over other BPs in improving femoral strength, mechanical fixation of implants, and bone volume around the implant [28, 29]. Despite the higher cost and relatively poor compliance compared to other anti-osteoporotic drugs, teriparatide may be a reasonable supplemental treatment to enhance the stability of cementless femoral stems in elderly patients after hemiarthroplasty for femoral neck fracture. However, there is no published report on the role of teriparatide in this situation.

The beneficial effects of teriparatide on implant fixation have been reported recently [13, 14]. Ohtori S et al. [13] prospectively studied 62 post-menopausal women and reported that teriparatide increased the quality of lumbar spine bone marrow and pedicle cortex. There was also a significantly lower incidence of pedicle screw loosening in the teriparatide group than in the risedronate or control groups. Inoue et al. [14] reported a cohort study of 29 post-menopausal women who underwent fusion surgery of the thoracic and/or lumbar spine and concluded that pre-operative teriparatide treatment might be an option for maximizing adherence of the pedicle screws to the bone at the time of fusion surgery. This study retrospectively analyzed the effect of teriparatide in preventing subsidence of the cementless femoral stem in elderly patients after bipolar hemiarthroplasty for femoral neck fracture. Teriparatide significantly reduced femoral stem migration compared to a control group of patients with calcium and vitamin D supplements only.

Since peri-prosthetic bone loss is most pronounced in the early post-operative period [30], decreases in bone regenerative capacity in the elderly may impact osteointegration at the prosthesis-bone interface and further contribute to subsidence of the femoral stem. The absence of osteointegration of the femoral stem is related to micro-movements at the prosthesis-bone interface. In this study, the adequacy of fit and fill of the femoral components in the medullary canal was examined, and all femoral stems filled the canal by more than 80%. Moreover, patients were allowed protection against weight-bearing due to a concern about subsidence that could result from inadequate osteointegration. However, significant subsidence of the femoral stem still occurred in the control group.

Improvements in osteointegration at the prosthesis-bone interface could allow elderly patients with femoral neck fracture to return to their daily activities and reduce morbidity and mortality. However, this study found no statistically significant differences in clinical outcomes, HRQoL, subsequent fracture, and mortality between those with and those without supplemental teriparatide treatment. The most likely reason for this is that migration of the prosthesis was limited in the control group. The femoral stem subsided initially, but stabilized at post-operative 12 weeks (Fig. 3).

This study has several limitations. First, it was a retrospective study, with all the inherent weaknesses and biases of such a study design. Teriparatide is approved by the Taiwanese FDA for treatment of osteoporosis only. Although evidence from studies utilizing animal models indicates teriparatide can improve osteointegration at the prosthesis-bone interface, this use in humans is “off label”

### Table 4 Functional Outcomes Assessments at Different Time Intervals

|                                         | Pre-injury | Post-operation |
|-----------------------------------------|------------|----------------|
|                                         |            | 3 months       |
|                                         |            | 6 months       |
|                                         |            | 9 months       |
|                                         |            | 12 months      |
|                                         | HHS score  | HHS score      |
| Group A                                 | 15.9 ± 9.1 | 56.2 ± 14.1    |
| Group B                                 | 15.4 ± 8.4 | 58.8 ± 10.1    |

|                                         |            | HHS score      |
|                                         |            | 70.9 ± 13.0    |
|                                         |            | 77.9 ± 10.6    |
|                                         |            | 83.6 ± 7.5     |
|                                     *Statistically significant (p < 0.05) |

|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |
|                                         | SF-12 PCS  |

### Table 5 Health-Related Quality of Life (HRQoL) Assessments at Different Time Intervals

|                                         | Pre-injury | Post-operation |
|-----------------------------------------|------------|----------------|
|                                         |            | 3 months       |
|                                         |            | 6 months       |
|                                         |            | 9 months       |
|                                         |            | 12 months      |
|                                         | SF-12 PCS  |
| Group A                                 | 45.9 ± 8.5 | 28.2 ± 11.3    |
| Group B                                 | 46.2 ± 9.8 | 29.2 ± 11.3    |
|                                         | 37.2 ± 10.8 | 38.1 ± 10.6    |
|                                         | 39.2 ± 11.0 | 40.3 ± 9.9     |
|                                         | 44.3 ± 11.6 | 45.0 ± 10.0    |

|                                         | SF-12 MCS  |
| Group A                                 | 59.2 ± 11.9 | 50.8 ± 11.1    |
| Group B                                 | 58.6 ± 10.9 | 51.7 ± 11.6    |
|                                         | 53.7 ± 9.3  | 53.4 ± 9.5     |
|                                         | 51.9 ± 10.6 | 52.4 ± 11.9    |
|                                         | 54.2 ± 10.5 | 54.5 ± 10.9    |

*Abbreviations: HHS, Harris hip score

*Values are shown as mean (standard deviation)
and it is difficult to obtain approval for a prospective study from the Ethics Committee and Institutional Review Board. Second, the patient number was small. Patients who took anti-osteoporotic drugs prior to surgery were excluded to avoid the confounding factors of medication. A single surgeon performed all hemiarthroplasties and the same post-operative rehabilitation protocol was used. The same prosthesis was implanted to avoid implant-related confounding factors. The strict inclusion criteria were meant to limit the study variables, but this also reduced the numbers of subjects and limited the power of the study to detect clinically significant differences. Although adequate sample sizes were determined to detect differences in subsidence of the femoral stem [7] and HHS [16], this study still may be underpowered to demonstrate significant differences. Third, in treating osteoporotic femoral neck fractures, the orthopedic community is divided between those using cementless hemiarthroplasty and those using cemented hemiarthroplasty. In order to avoid implant-related confounding factors, the current study focused on treatment with cementless hemiarthroplasty. Thus, the findings cannot be applied to teriparatide treatment with cemented hemiarthroplasty. Fourth, there are two different recombinant PTHs (PTH1-34 and PTH1-84), but only teriparatide (recombinant PTH1-34) is available in Taiwan. Although recombinant PTH1-84 also has had a clinical effect on fracture healing in post-menopausal women [31], similar results with its use cannot be assumed. There are also no comparative studies of the anabolic effects of the two drugs. Last, although differences between the two groups got statistical significance, differences between mean value of subsidence in the two groups is only about 0.7 mm. Clinical importance of this difference is limited. Meanwhile, measurements of the X-ray can not be so accurate, and this will also reduce the importance of the difference.

Conclusions
This study found a significant reduction of subsidence of the cementless femoral stem in elderly patients with femoral neck fractures who were provided teriparatide treatment. But teriparatide provided no significant benefits in terms of clinical outcome, HRQoL, subsequent fracture, and mortality. Further prospective randomized large-scale cohort studies are warranted to determine if the reduction in femoral stem subsidence will translate into significantly superior clinical outcomes and HRQoL, as a basis for evidence-based recommendations.

Abbreviations
AP, antero-posterior; ASA, American Society of Anesthesiologists; BMD, bone mineral density; BP, bisphosphonate; FDA, Food and Drug Administration; HHS, Harris Hip Score; HRQoL, health-related quality of life; IOF, International Osteoporosis Foundation; MCS, Mental Component Summary; PCS, Physical Component Summary; PTH, parathyroid hormone; SF-12, Short-Form-12; VTE, venous thrombo-embolism

Acknowledgments
We thank Miss Yu-Shuan Lin for recording radiographic and functional data and for assisting with the statistical analyses.

Funding
There was no external funding for this study.

Availability of data and materials
The dataset supporting the conclusions of this article is included within the article. Participants did not consent to public release of their data. However, data can be made available on request for researchers who meet the criteria for access to confidential data, from Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan.

Authors’ contributions
RWH, MSL, HNS, and WJS contributed substantially to the conception and design of the study. KCH, PYC, and SJL analyzed and interpreted the data. TWH drafted the article and revised it critically for important intellectual content. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This retrospective study was approved by the Ethics Committee and Institutional Review Board of the Chang Gung Memorial Hospital (98-10388), and all patients provided signed informed consent.

Author details
1Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan No. 6, West Section, Chia-Pu Road, Pu-Tz City, Chia-Yi Hsien 613, Taiwan. 2Department of Orthopaedic Surgery, Kaohsiung Chang Gung Memorial Hospital, 123 Dapi Road, Niao-song Dist, Kaohsiung City 83301, Taiwan. 3Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan. 4Chang Gung University, Taoyuan, Taiwan. 5PO CHENG Orthopedic Institute, 100 Bo-ai 2nd Road Zuoying District, Kaohsiung, Taiwan.

Received: 13 April 2016 Accepted: 23 June 2016
Published online: 19 July 2016

References
1. Gehrig LM, Lane JM, O’Connor M. Osteoporosis: management and treatment strategies for orthopaedic surgeons. Instr Course Lect. 2009;58: 817–32.
2. Schmidt AH, Broman JP, Duwelius PJ, et al. Geriatric trauma: the role of immediate arthroplasty. J Bone Joint Surg Am. 2013;95:2230–9.
3. Stephen R, Burnett J. Total hip arthroplasty: techniques and results. BCMJ. 2010;52:455–64.
4. Lindner T, Kanakaris NK, Marx B, et al. Fractures of the hip and osteoporosis: the role of bone substitutes. J Bone Joint Surg (Br). 2009;91:294–303.
5. Knusten AR, Ebrahimzadeh E, Longjohn DB, et al. Systematic analysis of bisphosphonate intervention on peri-prosthetic BMD as a function of stem design. J Arthroplasty. 2014;29:1292–7.
6. Khadot M, Inacio MC, Dell RM, et al. Association of bisphosphonate use and risk of revision after THA: outcomes from a US total joint replacement registry. Clin Orthop Relat Res. 2015;473:3412–20.
7. Friedl G, Radl R, Stihsen C, et al. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am. 2009;91:274–81.
8. Scott DF, Wolzt JN, Smith RR. Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial. J Arthroplasty. 2013;28:671–5.
9. Zhang D, Potty A, Vyas P, et al. The role of recombinant PTH in human fracture healing: a systematic review. J Orthop Trauma. 2014;28:57–62.
10. Kleerekoper M, Greenspan SL, Lewiecki EM, et al. Assessing the effects of teriparatide treatment on bone mineral density, bone micro-architecture, and bone strength. J Bone Joint Surg Am. 2014;96:e90.

11. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25:404-14.

12. Ohtori S, Inoue G, Orita S, et al. Teriparatide accelerates lumbar posterolateral fusion in women with post-menopausal osteoporosis: prospective study. Spine. 2012;37:E1464-1468.

13. Ohtori S, Inoue G, Orita S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine. 2013;38:E487-492.

14. Inoue G, Ueno M, Nakazawa T, et al. Teriparatide increases the insertion torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine. 2014;21:425-31.

15. Sweet MG, Sweet JM, Jeremiah MP, et al. Diagnosis and treatment of osteoporosis. Am Fam Physician. 2009;79:193-200.

16. Achten J, Parsons NR, Edlin RP, et al. A randomised controlled trial of total hip arthroplasty versus resurfacing arthroplasty in the treatment of young patients with arthrosis of the hip joint. BMC Musculoskelet Disord. 2010;11:8-13.

17. Engh CA, Massin P, Suthers KE. Roentgenographic assessment of the biologic fixation of porous-surfaced femoral components. Clin Orthop Relat Res. 1990;257:167-28.

18. Johnston RC, Fitzgerald Jr RH, Harris WH, et al. Clinical and radiographic evaluation of total hip replacement. A standard system of terminology for reporting results. J Bone Joint Surg Am. 1990;72:161-8.

19. Kim YH, Kim VE. Uncemented porous-coated anatomic total hip replacement. Results at six years in a consecutive series. J Bone Joint Surg (Br). 1993;75:6-13.

20. Baad-Hansen T, Kold S, Olsen N, et al. Excessive distal migration of fiber-mesh coated femoral stems: A randomized RSA study of 41 hips. Acta Orthop. 2011;82:308-14.

21. Konigsberg B, Hess R, Hartman C, et al. Inter- and intra-observer reliability of two-dimensional CT scan for total knee arthroplasty component malrotation. Clin Orthop Relat Res. 2014;472:212-7.

22. Osteoporosis Foundation Facts Statistics. International Osteoporosis Foundation website. http://www.iofbonehealth.org/facts-and-statistics/index.html [Accessed December 13, 2013].

23. Chen IJ, Chiang CY, Li YH, et al. Nationwide cohort study of hip fractures: time trends in the incidence rates and projections up to 2035. Osteoporos Int. 2015;26:681-8.

24. Kobayashi N, Inaba Y, Uchiyama M, et al. Teriparatide versus alendronate for the preservation of bone mineral density after total hip arthroplasty - a randomized controlled trial. J Arthroplasty. 2016;31:333-8.

25. Unnanuntana A, Saleh A, Mensah KA, et al. Atypical femoral fractures: what do we know about them? AAOS Exhibit Selection. J Bone Joint Surg Am. 2013;95:e8: 1-13.

26. Cross MB, Nam D, van der Meulen MC, et al. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture. J Bone Joint Surg. 2012;94:994-7.

27. Bloebaum RD, Willie BM, Mitchell BS, et al. Relationship between bone in-growth, mineral apposition rate, and osteoblast activity. J Biomed Mater Res A. 2007;81:505-14.

28. Keaveny TM, McClung MR, Wan X, et al. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone. 2012;50:165-70.

29. Dayer R, Brennan TC, Rizzoli R, et al. PTH improves titanium implant fixation more than pamidronate or renutrition in osteopenic rats chronically fed a low protein diet. Osteoporos Int. 2010;21:957-67.

30. Hol AM, van Grinsven S, Lucas C, et al. Partial versus unrestricted weight bearing after an uncemented femoral stem in total hip arthroplasty: recommendation of a concise rehabilitation protocol from a systematic review of the literature. Arch Orthop Trauma Surg. 2010;130:547-55.

31. Peichl P, Holzer LA, Maier R, et al. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93:1583-7.